title: Insight to drug delivery aspects for colorectal cancer.
abstract: Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide in human beings. Surgery, chemotherapy, radiotherapy and targeted therapies are the conventional four approaches which are currently used for the treatment of CRC. The site specific delivery of chemotherapeutics to their site of action would increase effectiveness with reducing side effects. Targeted oral drug delivery systems based on polysaccharides are being investigated to target and deliver chemotherapeutic and chemopreventive agents directly to colon and rectum. Site-specific drug delivery to colon increases its concentration at the target site, and thus requires a lower dose and hence abridged side effects. Some novel therapies are also briefly discussed in article such as receptor (epidermal growth factor receptor, folate receptor, wheat germ agglutinin, VEGF receptor, hyaluronic acid receptor) based targeting therapy; colon targeted proapoptotic anticancer drug delivery system, gene therapy. Even though good treatment options are available for CRC, the ultimate therapeutic approach is to avert the incidence of CRC. It was also found that CRCs could be prevented by diet and nutrition such as calcium, vitamin D, curcumin, quercetin and fish oil supplements. Immunotherapy and vaccination are used nowadays which are showing better results against CRC.
authors.affiliation: Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
authors.forename: Arvind
authors.initials: A
authors.lastname: Gulbake
authors.affiliation: Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
authors.forename: Aviral
authors.initials: A
authors.lastname: Jain
authors.affiliation: Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
authors.forename: Ashish
authors.initials: A
authors.lastname: Jain
authors.affiliation: Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
authors.forename: Ankit
authors.initials: A
authors.lastname: Jain
authors.affiliation: Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
authors.forename: Sanjay K
authors.initials: SK
authors.lastname: Jain
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D019496:Cancer Vaccines / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D004032:Diet; D004333:Drug Administration Routes; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007167:Immunotherapy
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004337:Drug Carriers
keywords: Colorectal cancer; Gene delivery; Receptor based targeted therapy
references.citation: Br Med Bull. 2002;64:201-25
references.pmid: 12421734
references.citation: Cancer Sci. 2004 Jan;95(1):85-90
references.pmid: 14720332
references.citation: Mol Cancer. 2010;9:217
references.pmid: 20712901
references.citation: Nanomedicine. 2010 Feb;6(1):179-90
references.pmid: 19447205
references.citation: Surg Oncol. 2015 Jun;24(2):61-6
references.pmid: 25770397
references.citation: Cancer Res. 2012 Jun 1;72(11):2757-67
references.pmid: 22427351
references.citation: Dis Colon Rectum. 2014 May;57(5):602-7
references.pmid: 24819100
references.citation: Vaccine. 2010 Jul 12;28(31):4937-44
references.pmid: 20653081
references.citation: Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii100-3
references.pmid: 23253923
references.citation: Oncotarget. 2014 Apr 30;5(8):2077-84
references.pmid: 24809457
references.citation: Int J Pharm. 2013 Jun 25;450(1-2):235-40
references.pmid: 23624084
references.citation: J Control Release. 2003 Aug 28;91(1-2):61-73
references.pmid: 12932638
references.citation: Cancer Immunol Immunother. 2012 Dec;61(12):2227-38
references.pmid: 22644735
references.citation: Crit Rev Oncol Hematol. 2010 Jun;74(3):193-202
references.pmid: 19700342
references.citation: Crit Rev Oncol Hematol. 2001 Oct;40(1):17-24
references.pmid: 11578913
references.citation: Cancer Res. 2013 Oct 1;73(19):5852-7
references.pmid: 24062312
references.citation: Int J Nanomedicine. 2013;8:809-19
references.pmid: 23589688
references.citation: Eur J Pharm Sci. 2003 Jan;18(1):3-18
references.pmid: 12554067
references.citation: J Clin Oncol. 1999 Sep;17(9):2941-53
references.pmid: 10561374
references.citation: Nat Prod Commun. 2010 Jun;5(6):915-8
references.pmid: 20614824
references.citation: J Pharm Pharmacol. 2008 Jan;60(1):35-44
references.pmid: 18088503
references.citation: PLoS One. 2013;8(11):e81919
references.pmid: 24260587
references.citation: Nanomedicine (Lond). 2012 Oct;7(10):1521-50
references.pmid: 22734611
references.citation: Pharm Res. 2003 Mar;20(3):351-9
references.pmid: 12669953
references.citation: Cancer Res. 2001 Mar 1;61(5):1796-8
references.pmid: 11280725
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Adv Exp Med Biol. 1998;451:531-7
references.pmid: 10026923
references.citation: Immunity. 2013 Jul 25;39(1):11-26
references.pmid: 23890060
references.citation: Am Fam Physician. 2012 May 15;85(10):964-71
references.pmid: 22612046
references.citation: Vaccine. 2005 Mar 18;23(17-18):2379-87
references.pmid: 15755632
references.citation: World J Gastroenterol. 2005 Feb 7;11(5):760-3
references.pmid: 15655840
references.citation: Hum Gene Ther. 2013 Jul;24(7):644-54
references.pmid: 23642239
references.citation: Gene Ther. 2000 Aug;7(16):1410-6
references.pmid: 10981668
references.citation: Br Med J. 1970 Nov 14;4(5732):420-2
references.pmid: 4921286
references.citation: Biochem Insights. 2008 Jul 22;2008:15-21
references.pmid: 24115841
references.citation: Oncologist. 2014 Jul;19(7):704-11
references.pmid: 24869929
references.citation: Histol Histopathol. 2006 Aug;21(8):867-72
references.pmid: 16691539
references.citation: Biomaterials. 1995 Nov;16(17):1313-8
references.pmid: 8573669
references.citation: J Immunother. 2011 Apr;34(3):320-6
references.pmid: 21389866
references.citation: Clin Cancer Res. 2011 Jun 1;17(11):3520-6
references.pmid: 21471425
references.citation: Curr Drug Deliv. 2008 Jul;5(3):215-9
references.pmid: 18673265
references.citation: Wien Med Wochenschr. 1993;143(16-17):416-9
references.pmid: 8273364
references.citation: Adv Drug Deliv Rev. 2004 Mar 3;56(4):491-509
references.pmid: 14969755
references.citation: J Natl Cancer Inst. 1995 Jul 5;87(13):982-90
references.pmid: 7629885
references.citation: Biomacromolecules. 2013 Aug 12;14(8):2798-806
references.pmid: 23837675
references.citation: Clin Cancer Res. 1999 Sep;5(9):2359-65
references.pmid: 10499605
references.citation: Cancer Lett. 2010 Dec 18;299(1):63-71
references.pmid: 20826046
references.citation: Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):329-38
references.pmid: 23485475
references.citation: Ann Surg Oncol. 2010 Apr;17(4):1168-76
references.pmid: 19936839
references.citation: Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):15-8
references.pmid: 15934495
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1276-82
references.pmid: 17431105
references.citation: Tumori. 2012 Mar-Apr;98(2):185-90
references.pmid: 22677983
references.citation: Mol Ther. 2014 Dec;22(12):2083-92
references.pmid: 25200008
references.citation: PDA J Pharm Sci Technol. 2007 Mar-Apr;61(2):121-30
references.pmid: 17479720
references.citation: J Pharm Pharmacol. 2008 May;60(5):615-23
references.pmid: 18416938
references.citation: Crit Rev Ther Drug Carrier Syst. 1996;13(3-4):185-223
references.pmid: 9016381
references.citation: J Natl Cancer Inst. 2010 Apr 7;102(7):493-501
references.pmid: 20179267
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):61-81
references.pmid: 10840193
references.citation: Cancer Immunol Immunother. 2012 Feb;61(2):157-68
references.pmid: 21858533
references.citation: Ann Intern Med. 2008 Nov 4;149(9):638-58
references.pmid: 18838718
references.citation: Nanoscale. 2013 Jan 7;5(1):178-83
references.pmid: 23076766
references.citation: J Clin Oncol. 1998 May;16(5):1788-94
references.pmid: 9586892
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Cancer Res. 2011 Aug 15;71(16):5393-9
references.pmid: 21724589
references.citation: Curr Cancer Drug Targets. 2011 Jan;11(1):103-10
references.pmid: 21062240
references.citation: Int J Nanomedicine. 2011;6:2419-27
references.pmid: 22072877
references.citation: Int J Mol Sci. 2013 Jan 24;14(2):2334-54
references.pmid: 23348928
references.citation: J Clin Oncol. 1999 Oct;17(10):3313-23
references.pmid: 10506635
references.citation: Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3466-70
references.pmid: 7682704
references.citation: J Mol Med (Berl). 1998 May;76(6):402-12
references.pmid: 9625297
references.citation: Cancer Res. 1999 Jun 15;59(12):2909-16
references.pmid: 10383154
references.citation: Cytokine Growth Factor Rev. 2005 Feb;16(1):35-53
references.pmid: 15733831
references.citation: J Urol. 2012 Mar;187(3):1071-9
references.pmid: 22266013
references.citation: Cancer J Sci Am. 1996 Mar-Apr;2(2):91-8
references.pmid: 9166506
references.citation: Clin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8
references.pmid: 16757216
references.citation: Vopr Onkol. 2003;49(2):189-92
references.pmid: 12785203
references.citation: Blood Rev. 2013 May;27(3):155-64
references.pmid: 23623928
references.citation: J Control Release. 2003 Jul 31;90(3):313-22
references.pmid: 12880698
references.citation: Cancer Immunol Immunother. 2013 May;62(5):919-29
references.pmid: 23197273
references.citation: Cancer Biother Radiopharm. 2008 Jun;23(3):285-91
references.pmid: 18593361
references.citation: Cancer Res. 2004 Jul 15;64(14):4995-5003
references.pmid: 15256474
references.citation: Semin Oncol. 2010 Oct;37(5):455-9
references.pmid: 21074060
references.citation: Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94
references.pmid: 14996493
references.citation: Recent Pat Endocr Metab Immune Drug Discov. 2013 Jan;7(1):1-10
references.pmid: 23215852
references.citation: Int J Med Sci. 2010;7(6):398-408
references.pmid: 21103076
references.citation: J Pharm Pharmacol. 2007 Mar;59(3):359-65
references.pmid: 17331338
references.citation: Vaccine. 1997 Apr-May;15(6-7):759-68
references.pmid: 9178479
references.citation: Cancer Res. 1998 Jun 1;58(11):2288-92
references.pmid: 9622060
references.citation: Oncogene. 2010 May 27;29(21):3033-43
references.pmid: 20383189
references.citation: J Microencapsul. 2013;30(7):643-56
references.pmid: 23544879
references.citation: J Pharm Pharm Sci. 2003 Jan-Apr;6(1):33-66
references.pmid: 12753729
references.citation: Am J Epidemiol. 2010 May 1;171(9):969-79
references.pmid: 20392864
references.citation: Int J Pharm. 2012 Aug 20;433(1-2):121-8
references.pmid: 22561793
references.citation: Adv Drug Deliv Rev. 2005 Jan 6;57(2):247-65
references.pmid: 15555741
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):107-12
references.pmid: 15671534
references.citation: J Am Soc Nephrol. 2008 Mar;19(3):433-42
references.pmid: 18256353
references.citation: J Leukoc Biol. 2006 Apr;79(4):652-62
references.pmid: 16415165
references.citation: Bull Math Biol. 2011 Jan;73(1):2-32
references.pmid: 20225137
references.citation: Anticancer Res. 2001 Mar-Apr;21(2B):1439-44
references.pmid: 11396228
references.citation: Int J Nanomedicine. 2012;7:2833-42
references.pmid: 22745546
references.citation: Jpn J Clin Oncol. 2008 Dec;38(12):793-802
references.pmid: 18988667
references.citation: Biomaterials. 2011 Nov;32(33):8645-53
references.pmid: 21875750
references.citation: Drug Des Devel Ther. 2013;7:195-9
references.pmid: 23569358
references.citation: Clin Cancer Res. 2000 Jan;6(1):34-41
references.pmid: 10656429
references.citation: Hum Gene Ther. 2004 Jul;15(7):699-708
references.pmid: 15242530
references.citation: Biomaterials. 1995 Apr;16(6):473-8
references.pmid: 7654874
references.citation: Int J Cancer. 2014 Jan 15;134(2):467-77
references.pmid: 23818211
references.citation: Pharm Res. 2002 Aug;19(8):1114-22
references.pmid: 12240936
references.citation: Cancer. 1988 Mar 15;61(6):1071-4
references.pmid: 3342367
references.citation: Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S23-6
references.pmid: 19343144
references.citation: Cancer J. 2010 May-Jun;16(3):196-201
references.pmid: 20526096
references.citation: Expert Rev Anticancer Ther. 2013 Jan;13(1):29-42
references.pmid: 23259425
references.citation: Postepy Biochem. 2007;53(3):228-38
references.pmid: 18399351
references.citation: J Drug Target. 2007 May;15(4):285-94
references.pmid: 17487697
references.citation: Bioconjug Chem. 1999 Sep-Oct;10(5):755-63
references.pmid: 10502340
references.citation: Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26
references.pmid: 19616446
references.citation: Cancer Res. 1999 Feb 1;59(3):676-83
references.pmid: 9973217
references.citation: Inflamm Res. 2013 Sep;62(9):823-34
references.pmid: 23868500
references.citation: Clin Ther. 2010 May;32(5):789-803
references.pmid: 20685491
references.citation: Pharm Res. 2002 Apr;19(4):396-402
references.pmid: 12033370
references.citation: J Biomed Nanotechnol. 2013 Jan;9(1):96-106
references.pmid: 23627072
references.citation: Expert Opin Biol Ther. 2007 Mar;7(3):391-6
references.pmid: 17309330
references.citation: Biomaterials. 2012 Sep;33(26):6186-93
references.pmid: 22687759
references.citation: J Control Release. 2003 Feb 14;88(1):95-103
references.pmid: 12586507
references.citation: Cold Spring Harb Perspect Biol. 2013 Feb;5(2). pii: a008722. doi: 10.1101/cshperspect.a008722
references.pmid: 23378584
references.citation: J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238-48
references.pmid: 7582260
references.citation: Mol Med Rep. 2012 Nov;6(5):955-60
references.pmid: 22895682
references.citation: J Pharm Sci. 2013 Feb;102(2):604-16
references.pmid: 23225084
references.citation: Br J Cancer. 1999 Nov;81(6):1009-16
references.pmid: 10576658
references.citation: Ther Deliv. 2012 Nov;3(11):1281-95
references.pmid: 23259249
references.citation: J Immunother. 2012 May;35(4):299-308
references.pmid: 22495387
references.citation: Hum Gene Ther. 2000 Jun 10;11(9):1269-75
references.pmid: 10890737
references.citation: Dig Dis Sci. 2014 Oct;59(10):2523-8
references.pmid: 24821462
references.citation: Cancer Biol Ther. 2010 Dec 1;10(11):1091-7
references.pmid: 20930514
references.citation: Genes Dev. 1999 Aug 1;13(15):1899-911
references.pmid: 10444588
references.citation: J Pharm Pharm Sci. 2001 May-Aug;4(2):138-58
references.pmid: 11466172
references.citation: Biochem Soc Trans. 2000 Feb;28(2):51-6
references.pmid: 10816098
references.citation: Eur J Pharm Sci. 2002 Aug;16(3):185-92
references.pmid: 12128173
references.citation: Colloids Surf B Biointerfaces. 2013 Apr 1;104:245-53
references.pmid: 23337120
references.citation: Drug Deliv. 2011 May;18(4):281-93
references.pmid: 21138335
references.citation: Lung Cancer. 2012 Apr;76(1):118-22
references.pmid: 22088939
references.citation: J Control Release. 2009 Jan 5;133(1):4-10
references.pmid: 18840484
references.citation: Cancer Gene Ther. 1996 Mar-Apr;3(2):121-30
references.pmid: 8729911
references.citation: Blood. 2009 Aug 27;114(9):1736-45
references.pmid: 19556425
references.citation: Expert Opin Biol Ther. 2006 Nov;6(11):1223-7
references.pmid: 17049018
references.citation: Eur J Cancer. 1999 Aug;35(8):1214-9
references.pmid: 10615232
references.citation: Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7021-5
references.pmid: 7624362